Reported 2026-06-15Lot BPC10-062026-499.11% purity · 11.80 mg
Open COA
Lyophilized Peptides
BPC-157
BPC-157 research peptide
A synthetic 15-residue peptide research material identified by the sequence GEPPPGKPADDAGLV.
CatalogBPC-PW
ManufacturerRemetide
PurityTarget ≥99% by RP-HPLC; lot result controls
PackResearch pack · supplied amount shown on product record
Price range: $55.00 through $85.00 Current catalog price; lot availability controls fulfillment.
AvailabilityIn stock
For laboratory research use only. Not for human or veterinary use.
BPC-157$55.00 – $85.00Price range: $55.00 through $85.00
01Lot documentationCOA and analytical-record model
02Defined specificationMethod and result remain lot specific
03Tracked fulfillmentShipping method and lot allocation confirmed at order review
04Responsible useNon-clinical laboratory context
Lot documentation
Current Certificate of Analysis
21 approved certificates are attached to this product record.
Reported 2026-06-15Lot BPC10-062026-499.11% purity · 11.80 mg
Open COA
Reported 2026-04-29Lot BPC15-042026-799.12% purity · 17.54 mg
Open COA
Reported 2026-04-25Lot BPC15-042026-498.44% purity · 16.90 mg
Open COA
Reported 2026-04-25Lot BPC15-042026-498.44% purity · 16.90 mg
Open COA
Reported 2026-04-23Lot BPC20-042026-199.12% purity · 20.50 mg
Open COA
Reported 2026-03-21Lot BPC15-01092026-J99.55% purity · 16.75 mg
Open COA
Reported 2026-02-25Lot BPC11182025-J99.94% purity · 11.65 mg
Open COA
Reported 2026-02-07Lot BFB100-620302027799.092% purity · 101.32 mg
Open COA
Reported 2025-11-21Lot BPC11122025-J99.247% purity · 10.65 mg
Open COA
Reported 2025-10-16Lot BPC1010112025-1599.513% purity · 10.59 mg
Open COA
Reported 2025-09-13Lot SEMX 1009052025-0699.683% purity · 9.80 mg
Open COA
Reported 2025-09-13Lot GLOW09082025-J99.64% purity · GHK-Cu- 53.21 mg BPC-157- 12.55 mg Thymosin Beta-4- 12.26 mg
Open COA
Reported 2025-09-13Lot MEL209032025-J99.95% purity · 8.83 mg
Open COA
Reported 2025-09-13Lot AOD09082025-J99.727% purity · 5.14 mg
Open COA
Reported 2025-09-13Lot CGSM09032025-J99.89% purity · Caglilintide- 9.55 mg Semaglutide- 10.16 mg
Open COA
Reported 2025-09-13Lot BPC09032025-J99.368% purity · 12.02 mg
Open COA
Reported 2025-08-13Lot 253030198.2% purity · 4.63 mg
Open COA
Reported 2025-08-05Lot BPC1007122025-1299.37% purity · 12.81 mg
Open COA
Reported 2025-07-16Lot BPC10072025-N99.34% purity · 11.80 mg
Open COA
Reported 2025-06-07Lot BOU-110962-2025-1099.28% purity · 10.71 mg
Open COA
Technical information
Chemical & material record
Presented in a scientific-catalog format so the material can be evaluated by identity, form and documentation before purchase.
- Identity
- BPC-157 acetate
- Synonyms
- BPC-157 research peptide
- CAS number
- 1628202-19-6
- Molecular formula
- C62H98N16O22 · X(C2H4O2)
- Formula weight
- 1,419.5 Da, excluding variable acetate contribution
- Sequence / identity note
- GEPPPGKPADDAGLV
- Manufacturer
- Remetide
- Manufacturing role
- Custom peptide synthesis and manufacture
- Form
- Lyophilized, non-sterile research material
- Purity specification
- Target ≥99% by RP-HPLC; lot result controls
- Storage
- -20°C, dry and protected from light; follow lot documentation
- Pack size
- Research pack · supplied amount shown on product record
- Catalog number
- BPC-PW
Research context
Published research & product context
Published literature is presented separately from lot-specific identity, purity and analytical results.
BPC-157 is a pentadecapeptide described in published literature as a fragment associated with body protection compound. Research has examined the peptide in cell-migration, cytoskeletal and multiple non-clinical model systems.
In primary rat tendon fibroblasts, 2 µg/mL BPC-157 was reported to increase cell migration and F-actin formation. Other cited studies evaluated inflammatory and gastric-lesion endpoints in rodents. These findings are preclinical and do not establish human safety or efficacy.
Selected published findings
- Increased migration and F-actin formation in primary rat tendon fibroblasts in a published in-vitro study.
- Was evaluated in rodent models involving inflammatory and gastric-lesion endpoints.
References and product citations 2
- Chang, C.H., Tsai, W.C., Lin, M.S., et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology 110(3), 774–780 (2011).
- Sikiric, P., Seiwerth, S., Rucman, R., et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Neuropharmacology 14(8), 818–829 (2016).
Literature interpretation: This summary describes published experimental literature and is not a lot specification, clinical claim, use instruction or representation that the supplied research material will reproduce a published result. This record intentionally excludes dosing, administration, clinical outcomes, patient eligibility and therapeutic comparisons.
Intended laboratory context
Illustrative applications
- Analytical method development
- In-vitro laboratory investigation
- Identity comparison
- Research protocol development
Documentation package
Documentation
- PDFCertificate of AnalysisSample
- PDFHPLC chromatogramSample
- PDFMass-spectrometry summarySample
- PDFHandling statementSample
For laboratory research workflows only. Not for administration to humans or animals and not supplied with dosing or reconstitution guidance.
Need a current record?
Documentation before decision-making.
Reference BPC-PW and the applicable lot when contacting technical support. Published files support evaluation but do not replace the approved lot COA or material specification.
View documentation model